+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

Psoriatic Arthritis Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update - Product Thumbnail Image

Psoriatic Arthritis Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

  • Report
  • August 2022
  • 465 Pages
  • Global
From
Clinical Trials Sector Scorecard, Q2 2022 Update - Thematic Research - Product Thumbnail Image

Clinical Trials Sector Scorecard, Q2 2022 Update - Thematic Research

  • Report
  • June 2022
  • 16 Pages
  • Global
From
Fibromyalgia (Fibromyalgia Syndrome) - Global Clinical Trials Review, H2, 2021 - Product Thumbnail Image

Fibromyalgia (Fibromyalgia Syndrome) - Global Clinical Trials Review, H2, 2021

  • Clinical Trials
  • December 2021
  • 327 Pages
  • Global
From
PharmSource - Bio/Pharma CapEx Trends - 2019 Edition - Product Thumbnail Image

PharmSource - Bio/Pharma CapEx Trends - 2019 Edition

  • Report
  • December 2019
  • 32 Pages
  • Global
From
Clinical Trials Sector Scorecard - Thematic Research - Product Thumbnail Image

Clinical Trials Sector Scorecard - Thematic Research

  • Report
  • October 2021
  • 24 Pages
  • Global
From
Osteoporosis: Global Drug Forecast and Market Analysis to 2027 - Product Thumbnail Image

Osteoporosis: Global Drug Forecast and Market Analysis to 2027

  • Report
  • April 2018
  • 195 Pages
  • Global
From
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 99 Pages
  • Global
From
Parkinson's Disease: Global Drug Forecast and Market Analysis to 2026 - Product Thumbnail Image

Parkinson's Disease: Global Drug Forecast and Market Analysis to 2026

  • Report
  • May 2018
  • 127 Pages
  • Global
From
Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update - Thematic Research - Product Thumbnail Image

Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update - Thematic Research

  • Report
  • June 2022
  • 16 Pages
  • Global
From
Neuroimmunology Drug Development - Thematic Research - Product Thumbnail Image

Neuroimmunology Drug Development - Thematic Research

  • Report
  • April 2022
  • 163 Pages
  • Global
From
Drug Development Sector Scorecard - Q4 2021 Update - Thematic Research - Product Thumbnail Image

Drug Development Sector Scorecard - Q4 2021 Update - Thematic Research

  • Report
  • December 2021
  • 16 Pages
  • Global
From
Pharma Industry Mergers and Acquisitions Deals by Top Themes in 2022 - Thematic Intelligence - Product Thumbnail Image

Pharma Industry Mergers and Acquisitions Deals by Top Themes in 2022 - Thematic Intelligence

  • Report
  • February 2023
  • 22 Pages
  • Global
From
UCB SA Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis - Product Thumbnail Image

UCB SA Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

  • Company Profile
  • April 2025
  • 50 Pages
From
Comprehensive Report on UCB, including SWOT, PESTLE and Business Model Canvas - Product Thumbnail Image

Comprehensive Report on UCB, including SWOT, PESTLE and Business Model Canvas

  • SWOT Analysis
  • August 2023
  • 90 Pages
From
UCB SA (UCB) - Financial and Strategic SWOT Analysis Review - Product Thumbnail Image

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

  • SWOT Analysis
  • November 2024
  • 70 Pages
From
UCB S.A. - Company Profile and SWOT Analysis - Product Thumbnail Image

UCB S.A. - Company Profile and SWOT Analysis

  • SWOT Analysis
  • January 2024
  • 49 Pages
From
Loading Indicator